Gelatin-coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment

Chemical Biology & Drug Design
Sorina SuarasanSimion Astilean

Abstract

This study presents the design of a gold nanoparticle (AuNPs)-drug system with improved efficiency for the treatment of acute myeloid leukemia. The system is based on four different FLT3 inhibitors, namely midostaurin, sorafenib, lestaurtinib, and quizartinib, which were independently loaded onto gelatin-coated gold nanoparticles. Detailed investigation of the physicochemical properties of the formed complexes lead to the selection of quizartinib-loaded AuNPs for the in vitro evaluation of the biological effects of the formed complex against OCI-AML3 acute myeloid leukemia cells. Viability tests by MTT demonstrated that the proposed drug complex has improved efficacy when compared with the drug alone. The obtained results constitute a premise for further in vivo investigation of such drug vehicles based on AuNPs. To the best of our knowledge, this is the first study that investigates the delivery of the above-mentioned FLT3 inhibitors via gelatin-coated gold nanoparticles.

References

Aug 1, 1980·International Journal of Cancer. Journal International Du Cancer·S TsuchiyaK Tada
Nov 13, 1999·Nature Cell Biology·S Huang, D E Ingber
Sep 13, 2003·Leukemia·M Levis, D Small
Nov 25, 2003·Apoptosis : an International Journal on Programmed Cell Death·M CornelissenL de Ridder
Aug 10, 2004·Biophysical Journal·Dakota WatsonMirianas Chachisvilis
Nov 4, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Simon YoungAntonios G Mikos
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Apr 25, 2008·Blood Reviews·Chad M Craig, Gary J Schiller
Oct 28, 2008·Cancer Treatment Reviews·Andrea Kuendgen, Ulrich Germing
Jul 16, 2010·Journal of Oncology·Lagadinou D EleniSpyridonidis Alexandros
Sep 8, 2011·Expert Opinion on Investigational Drugs·Steven Knapper
Feb 7, 2012·European Journal of Medicinal Chemistry·Natalia MiklášováEvamarie Hey-Hawkins
Dec 25, 2012·Colloids and Surfaces. B, Biointerfaces·Sorina SuarasanSimion Astilean
Apr 25, 2013·International Journal of Hematology·Michael R Grunwald, Mark J Levis
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Jun 3, 2014·Therapeutic Advances in Hematology·Seth A WanderAmir T Fathi
Aug 6, 2014·International Journal of Nanomedicine·Ciprian TomuleasaIoana Berindan-Neagoe
Jan 13, 2015·Current Opinion in Hematology·Robert J OrlowskiSelina M Luger
Apr 4, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betül OranRichard E Champlin
Jun 4, 2015·Colloids and Surfaces. B, Biointerfaces·Sorina SuarasanSimion Astilean

❮ Previous
Next ❯

Citations

Sep 23, 2016·Romanian Journal of Internal Medicine = Revue Roumaine De Médecine Interne·Anca BojanCiprian Tomuleasa
Mar 16, 2017·Journal of Cellular Physiology·Ciprian TomuleasaStefan O Ciurea
Oct 21, 2017·Therapeutic Advances in Hematology·Molly M GalloglyBrenda W Cooper
Dec 24, 2018·Drug Development and Industrial Pharmacy·Singkome TimaSongyot Anuchapreeda
Aug 9, 2019·Journal of Clinical Medicine·Valentina SasUNKNOWN Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
Sep 6, 2020·Journal of Cellular and Molecular Medicine·Patric TeodorescuCiprian Tomuleasa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Mark Levis
Clinical Advances in Hematology & Oncology : H&O
Jeffrey E Lancet
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Xiao-juang ZhouYun-feng Shen
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Xue LiuGuangsen Zhang
© 2021 Meta ULC. All rights reserved